MedPath

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Phase 1
Completed
Conditions
Neovascular Age-related Macular Degeneration (NVAMD)
Diabetic Macular Edema (DME)
Interventions
Registration Number
NCT05919693
Lead Sponsor
EyeBiotech Ltd.
Brief Summary

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Detailed Description

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye
Exclusion Criteria
  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Dose 3EYE103Part 1 MAD Portion Dose 3 - Mid-High Dose
Dose 1EYE103Part 1 MAD Portion Dose 1 - Low Dose
Dose 2EYE103Part 1 MAD Portion Dose 2 - Low-Mid Dose
DME Medium DoseEYE103Part 2 Naïve DME monotherapy Medium Dose
DME High DoseEYE103Part 2 Naïve DME monotherapy High Dose
Naïve NVAMD Medium DoseEYE103Part 2 Naïve NVAMD combination therapy Medium Dose
Naïve NVAMD High DoseEYE103Part 2 Naïve NVAMD combination therapy High Dose
Experienced NVAMD Medium DoseEYE103Part 2 Experienced NVAMD combination therapy Medium Dose
Experienced NVAMD High DoseEYE103Part 2 Experienced NVAMD combination therapy High Dose
Dose 4EYE103Part 1 MAD Portion Dose 4 - High Dose
Primary Outcome Measures
NameTimeMethod
Adverse Events3 months

Adverse Events

Secondary Outcome Measures
NameTimeMethod
Best-corrected Visual Acuity3 months

Best-corrected Visual Acuity

Trial Locations

Locations (31)

San Antonio, TX

🇺🇸

San Antonio, Texas, United States

Ciudad Autonoma Buenos Aires

🇦🇷

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Lakewood, CO

🇺🇸

Lakewood, Colorado, United States

Germantown, TN

🇺🇸

Germantown, Tennessee, United States

Caba, Argentina

🇦🇷

Caba, Argentina

Amarillo, TX

🇺🇸

Amarillo, Texas, United States

Modesto, CA

🇺🇸

Modesto, California, United States

West Columbia, SC

🇺🇸

West Columbia, South Carolina, United States

Pompano Beach

🇺🇸

Pompano Beach, Florida, United States

Dallas, TX

🇺🇸

Dallas, Texas, United States

Nashville, TN

🇺🇸

Nashville, Tennessee, United States

Bellaire, TX

🇺🇸

Bellaire, Texas, United States

London, England

🇬🇧

London, England, United Kingdom

Plano, TX

🇺🇸

Plano, Texas, United States

Katy, TX

🇺🇸

Katy, Texas, United States

McAllen, TX

🇺🇸

McAllen, Texas, United States

Arecibo, PR

🇵🇷

Arecibo, Puerto Rico

The Woodlands, TX

🇺🇸

The Woodlands, Texas, United States

Round Rock, TX

🇺🇸

Round Rock, Texas, United States

Phoenix, AZ

🇺🇸

Phoenix, Arizona, United States

Colorado Springs, Colorado

🇺🇸

Colorado Springs, Colorado, United States

Bakersfield, CA

🇺🇸

Bakersfield, California, United States

Mountain View, CA

🇺🇸

Mountain View, California, United States

Lemont, NV

🇺🇸

Lemont, Illinois, United States

London, UK

🇬🇧

London, United Kingdom

Reno, NV

🇺🇸

Reno, Nevada, United States

Hagerstown, MD

🇺🇸

Hagerstown, Maryland, United States

Knoxville, TN

🇺🇸

Knoxville, Tennessee, United States

Abilene, TX

🇺🇸

Abilene, Texas, United States

Austin, TX

🇺🇸

Austin, Texas, United States

Sacramento, CA

🇺🇸

Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath